Cardiol Therapeutics Inc
Commented by André Will-Laudien on November 7th, 2023 | 07:00 CET
Caution: New Corona wave ahead? BioNTech, Pfizer, Cardiol Therapeutics and MorphoSys on the performance test bench
Smouldering lawsuits from vaccinated patients experiencing severe side effects have caused investors to doubt BioNTech and Pfizer in recent months. Will the plaintiffs be successful in court? This is rather unlikely, as the vaccine manufacturers can always invoke the time component in the fight against the pandemic. After all, what the WHO and all governments wanted was delivered: A quick solution! Moreover, these vaccines were finally approved by well-known health institutes. The biotech investment segment will become exciting again as winter approaches. The infection figures with the new coronavirus variants are rising noticeably again, and around 15% of the population wishes to get vaccinated. Where are the opportunities for investors?
Read
Commented by Fabian Lorenz on November 1st, 2023 | 06:10 CET
More than 300% share price opportunity: BioNTech, Morphosys and Cardiol Therapeutics
Study results, along with acquisitions by Big Pharma, are the drivers of biotech company share prices. However, in the current challenging stock market environment, even positive data can be overlooked. But this opens up opportunities for investors with a little more staying power. Sooner or later, the information is recognized, and stock prices rise, or a pharmaceutical giant makes a move. At BioNTech, for example, the price reaction to the long-awaited news from the cancer pipeline has failed to materialize. Analysts are also cautious. Cardiol Therapeutics is a different story. The Canadians have taken on the fight against heart disease and are making significant progress in their research. The share had more than doubled to EUR 1.08 by the summer. Several analysts see the current setback as a buying opportunity. Experts are also giving the thumbs up to German biotech pioneer Morphosys.
Read
Commented by Stefan Feulner on October 25th, 2023 | 07:20 CEST
BioNTech, Cardiol Therapeutics, Paion - Rising Attractiveness and Lots of Movement
The current geopolitical uncertainties with escalating conflicts in Ukraine and Israel, as well as fears of recession with continued high inflation, have also impacted the capital-intensive biotech sector. In the past week, the Nasdaq Biotech Index fell to its lowest level of the year. Since the beginning of the year, the loss amounts to almost 12%. This level should offer excellent entry opportunities for long-term investors, as many biotech companies are currently very well-positioned and attractively valued.
Read
Commented by Armin Schulz on October 17th, 2023 | 07:00 CEST
BioNTech, Cardiol Therapeutics, Bayer - Redefining the frontiers of medicine
The biotech and pharmaceutical sector is playing an increasingly important role in our society. This can be attributed primarily to demographic change, as people worldwide are getting older and older. As life expectancy increases, so does the prevalence of age-related diseases such as cancer and heart disease. These two disease categories place a significant burden on healthcare systems and require innovative solutions for diagnosis, treatment and prevention. After Corona, this could be where the next global blockbuster is developed. We look at three interesting candidates.
Read
Commented by Fabian Lorenz on October 5th, 2023 | 07:10 CEST
Buy biotech stocks now? BioNTech, Morphosys and Cardiol Therapeutics in check
In times of high interest rates, the wheat is separated from the chaff, even in the biotech sector. After all, young research-based companies, in particular, have a high demand for capital. But at the moment, all companies are being lumped together. This opens up clear buying opportunities because some have full coffers. BioNTech belongs to this group. Thanks to the COVID-19 vaccine, research is fully financed. The same goes for Cardiol Therapeutics. The share of the Canadians is one of the summer's high flyers, and the recent price setback offers an entry opportunity. The analysts' price target is over 300% above the current level. And what do analysts say about the German biotech veteran Morphosys? Goldman Sachs has tripled its price target.
Read
Commented by Nico Popp on September 27th, 2023 | 07:10 CEST
Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics
High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!
Read
Commented by Stefan Feulner on September 12th, 2023 | 07:10 CEST
Trend-setting developments at Covestro, Cardiol Therapeutics and 2G Energy AG
The holiday season is drawing to a close. By Tuesday at the latest, when the last German state concludes its school holidays, every investment banker will be back at their screens, closely monitoring the most exciting events on the markets. Despite the summer lull, there have been many impactful events, especially in second-tier companies, which could significantly impact share prices in the near future.
Read
Commented by Armin Schulz on September 6th, 2023 | 08:00 CEST
BioNTech, Cardiol Therapeutics, Bayer - Tiger mosquitoes, and rising Corona numbers bring biotech back in focus
Corona infections are already rising, even though autumn has not even begun. Hospitals are already fearing a high burden during the winter. Gerald Gaß, the Chairman of the Board of the German Hospital Federation, advised high-risk patients, their close contacts and healthcare workers to keep their flu and COVID-19 vaccinations up to date. Due to constant stress triggered by crises and workload-related pressures, the number of heart patients have also increased in recent years. At the end of August, entire neighborhoods and streets in Paris were closed off to spray insecticides against tiger mosquitoes, which spread diseases like dengue and Zika viruses, among others. This is reason enough for us to examine three companies fighting these threats.
Read
Commented by Nico Popp on August 30th, 2023 | 07:00 CEST
Course Rockets of Yesterday - and Tomorrow: Innocan Pharma, BioNTech, Cardiol Therapeutics
According to the information service IQVIA, dietary supplements generate almost EUR 3 billion in sales in Germany - and the trend is rising. More and more people are paying attention to their health and are not satisfied when the doctor says, "You are healthy." In fact, there is still a lot of upside potential for healthy people, too - for example, when it comes to reducing stress, improving sleep or strengthening the body's own defenses. Today, we highlight three stocks that could benefit from increased health awareness.
Read
Commented by André Will-Laudien on August 23rd, 2023 | 07:00 CEST
Climate change or just a heat wave? - BioNTech, Cardiol Therapeutics, and Redcare Pharmacy deliver!
Whether this consistently warm summer already documents a pronounced climate change is questionable. The older ones among us remember that there were already very hot summers before and that even in the last 30 years, there was rarely snow at Christmas. However, human life is simply too short for significant conclusions. Therefore, long-term weather records have to be consulted. There will probably be a slight increase in average temperatures, but we will get little information about when the next ice age will hit us. For many politicians, the current weather trends fit perfectly into the chain of arguments in favor of radical legislative proposals. Perhaps, however, the caprices of the weather are only the offshoots of the approaching El Nino. The stock market also follows changing trends; after the flood, an ebb could now be imminent. Selection remains key!
Read